Investors are more bullish on shares of Aquinox Pharmaceuticals, Inc. lately as implied by the motion in short interest. The company experienced a fall in short interest of -20.60% as of the latest report on October 13, 2017. Short interest fell from 721,680 to 573,008 over that period. The short-interest ratio decreased to 12.0 and the short interest percentage is 0.02% as of October 13.
Additionally, here are a few investment firms who have increased or decreased their stake in (AQXP). As of quarter end Alyeska Investment Group, L.p. had acquired a total of 131,364 shares growing its stake by 89.9%. The value of the investment in AQXP increased from $2,439,000 to $3,905,000 increasing 60.1% quarter to quarter. Boxer Capital, LLC downsized its holdings by shedding 352,753 shares a decrease of 40.2% as of 06/30/2017. Boxer Capital, LLC owns 525,000 shares valued at $7,387,000. The total value of its holdings decreased 49.6%.
As of the end of the quarter Ghost Tree Capital, LLC had bought 75,000 shares growing its position 33.3%. The value of the investment in Aquinox Pharmaceuticals, Inc. went from $3,755,000 to $4,221,000 a change of 12.4% quarter over quarter. Cutler Group LP trimmed its ownership by selling 130 shares a decrease of 43.3% in the quarter. Cutler Group LP now controls 170 shares with a value of $2,000. The value of the position overall is up by inf%.
The company is up since yesterday’s close of $11.27. Shares of the company are trading at $11.27 impressively lower than the 50 day moving average of $13.49 and which is well below the 200 day moving average of $14.09. The 50 day moving average went down $-2.22 or -16.44% whereas the 200 day average was down by -20.03%.
In the latest earnings report the EPS was $-1.88 and is expected to be $-2.15 for the current year with 23,464,000 shares presently outstanding. Next quarter’s EPS is forecasted to be $-0.61 and the next full year EPS is projected to be $-2.23.
Aquinox Pharmaceuticals, Inc., launched on May 25, 2007, is a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. The Business’s primary focus is anti-inflammatory product candidates targeting the Src Homology 2 (SH2)-containing inositol-5-phosphatase 1 (SHIP1) enzyme, which is a regulator of a cellular signaling pathway in immune cells, known as the phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) pathway. Its product candidate, AQX-1125, is a small molecule activator of SHIP1 suitable for oral, once daily dosing. The Company is developing AQX-1125 as a treatment in interstitial cystitis/bladder pain syndrome (IC/BPS), a chronic inflammatory disease of the bladder. It has completed and reported results from its Leadership trial, which is a multicenter, randomized, double-blind, placebo-controlled, Phase II clinical trial investigating the ability of 200 milligrams oral, once daily AQX-1125 to reduce pain and urinary symptoms in female patients with IC/BPS..